Item Details
AstraZeneca Cooperation Included in Kazakhstan’s $1.3 Billion Alatau Agreements
On 3 November, Kazakhstan included cooperation with AstraZeneca and Crescent Meditours in its Alatau City investment agreements, covering medical infrastructure development, investment attraction and scientific exchange. The nine agreements have a combined investment potential of $1.3 billion, but no separate healthcare project value was disclosed. This creates opportunities for hospital operators, pharmaceutical suppliers, medical technology companies and healthcare investors; HPC can support healthcare partnerships and supplier introductions.
Get in Touch
We’ll get back to you shortly.